Explore every episode of the podcast Rheumnow Podcast

Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.

Features Dr. Jack Cush, Editor at RheumNow.com.

Show Notes: - Breckenridge Pharmaceutical received FDA approval for their generic version of tofacitinib on 6/4/26. 5 mg and 10 mg tablets are now available in the U.S. market, for both adult and pediatric use. Tofacitinib Tablets are manufactured in Martorelles, Spain. https://t.co/oAh0KQSFgs

- TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/NFIap7DSOr  

- BE BOLD: Bimekizumab Beats Risankizumab (LB0001) –H2H trial bimekizumab vs risankizumab in PsA for 24 weeks. At week 16; BKZ better than RZB,  p=0.0058). This advantage was maintained out to week 24 (55% vs 44%; p 0.0001).

- RA-BRIDGE and RA-BRANCH: FDA mandated study of the risk of venous thromboembolic events (VTE) taking baricitinib (BARI) or TNF inhibitors. The incidence rate was 0.79/100 PY for BARI combined versus 0.51/100 PY for TNFi. The hazard ratio was 1.606 (95% CI 0.969–2.660), with the upper CI exceeding the pre-specified NI margin of 1.8.  Baricitinib (neither dose) was associated with a higher risk of MACE (HR 1.06), all-cause mortality (HR 0.97), arterial thromboembolism (HR 1.27), or opportunistic infections (HR 1.25).  

- Probiotics in Psoriatic Arthritis. (POS0290)    66 PsA patients randomized to receive either placebo or probiotic containing lactobacillus and bifidobacterium strains for 12 weeks.  This trial proves no significant effect with oral probiotic supplementation in PsA. 

- CLE and smoking. Smoking reduces efficacy of antimalarials & worsens dz activity & damage. Advocate for smoking cessation! @Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ

- Risk of Psoriasis is increased 19% by long-term exposure to Particulate Matter (PM2.5 & PM10; adjHR 1.19), while short-term exposure increases risk of psoriasis exacerbation (adjusted OR 1.03). Stronger in younger, urban, lower SES, ever-smokers, & comorbid allergies https://t.co/pd6S13RG1B

Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.

Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the EULAR 2026 meeting in London.

Join Drs. Bella Mehta, Jack Cush, Janet Pope, and Jon Kay for a focused conversation on the latest in rheumatoid arthritis care from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping RA practice right now.

Join Drs. Jack Cush, Alfred Kim, Janet Pope, and Yuz Yusof for a focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.

Join Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026.

This focused conversation explores new clinical data, evolving treatment strategies, and practical approaches to managing PsA in everyday practice. From advances in biologic and targeted therapies to ongoing challenges in diagnosis, disease monitoring, and patient care, the panel shares key insights and take-home messages that every rheumatology clinician should know.

Tune in for expert perspectives, clinical pearls, and a comprehensive look at what's shaping the future of psoriatic arthritis management.

2026 EULAR Preview Beyond BMI: Altered Body Composition in Rheumatoid Arthritis CAR-T For Rheumatoid Arthritis This Is a Woman’s World: Women's Health in Rheumatic Disease Low dose Blinatumomab: Many Relapse with an Unexpected Surprise Doctor's Orders or Patient's Choice: BACH study findings Another Way to Leverage NK Cells to Kill B Cells, This Time Without CARs Digital Patient Education in RA Making Methotrexate More Effective Are we failing in the treatment of RA-ILD? Using AI to Predict Progression to RA Treat to Target Works in Elderly Onset RA RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk Improving Referrals for Inflammatory Arthritis Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease

2026 EULAR Preview Imaging in Subclinical Psoriatic Arthritis Dietary Interventions in PsA This Is a Woman’s World: Women's Health in Rheumatic Disease Impact of Synovial Biopsy-Driven Therapeutic Stratification in PsA Can We Stop PsA Before it Starts? BE BOLD: Going Where No PsA Trial Has Gone Before BMI Outranks Treatment in PsA Outcomes? Debate: Combination Therapies for Inflammatory Arthritis? Combination Biologics in PsA: MRI Findings from AFFINITY Combination Therapy in SpA The Case for Dual Pathway Blockade in Refractory PsA The AFFINITY Study: Combination Treatment in PsA PsA Potpourri: Probiotics & Head-to-Head Data Transition from Psoriasis to Psoriatic Arthritis MACE and Safety Profile of bDMARDs/JAKis in axSpA and PsA Guselkumab Delivers Across the PsA Disease Spectrum: APEX Trial

2026 EULAR Preview CAR-T For Rheumatoid Arthritis What Happens when CAR-T Fails Managing Disease Recurrence Management of Relapses After CAR-T Therapy in SLE, SSc and IIM How Many CAR-Ts Do We Need to Test Drive?

Guselkumab Delivers Across the PsA Disease Spectrum: APEX Trial RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk Improving Referrals for Inflammatory Arthritis" Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease

Are we failing in the treatment of RA-ILD? Using AI to Predict Progression to RA Treat to Target Works in Elderly Onset RA

MACE and Safety Profile of bDMARDs/JAKis in axSpA and PsA How Many CAR-Ts Do We Need to Test Drive? Making Methotrexate More Effective

Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Day 4 of the EULAR 2026 Congress. Abstracts discussed included:

LB001 LB002 LB003 LB005 LB007 LB009 RA Plenary POS1350

Debate: Combination Therapies for Inflammatory Arthritis? Combination Biologics in PsA: MRI Findings from AFFINITY Combination Therapy in SpA Digital Patient Education in RA The Case for Dual Pathway Blockade in Refractory PsA The AFFINITY Study: Combination Treatment in PsA PsA Potpourri: Probiotics & Head-to-Head Data Transition from Psoriasis to Psoriatic Arthritis

Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Days 3 of the EULAR 2026 Congress. Abstracts discussed included: OP0348  POS0290  OP0342  POS1068  POS0201  POS0288

BE BOLD: Going Where No PsA Trial Has Gone Before BMI Outranks Treatment in PsA Outcomes? What Happens when CAR-T Fails Managing Disease Recurrence Management of Relapses After CAR-T Therapy in SLE, SSc and IIM Doctor's Orders or Patient's Choice: BACH study findings Another Way to Leverage NK Cells to Kill B Cells, This Time Without CARs

Low dose Blinatumomab: Many Relapse with an Unexpected Surprise Can We Stop PsA Before it Starts? Impact of Synovial Biopsy-Driven Therapeutic Stratification in PsA

Join Dr. Jack Cush and RheumNow.com faculty for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Days 1 & 2 of the EULAR 2026 Congress. Abstracts discussed included:

OP0177 OP0244   OP001 OP008 OP0205  OP018 OP0204 POS0788

Imaging in Subclinical Psoriatic Arthritis CAR-T For Rheumatoid Arthritis This Is a Woman’s World: Women's Health in Rheumatic Disease Dietary Interventions in PsA

2026 EULAR Preview - Dr. Jack Cush ‘Strong’ Treatment Predictions in Inflammatory Myositis - Dr. Janet Pope Beyond BMI: Altered Body Composition in Rheumatoid Arthritis - Dr Mrinalini Dey Why PROMS Matter in the Care of People with Lupus - Dr. Mrinalini Dey

Dr. Jack Cush reviews the news, journal articles and missed quiz question.

Dr. Jack Cush talks of birthdays, Quizes and journal articles this week on the podcast.

Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.

Dr Jack Cush reviews the news and journal reports from last weekon rheumnow.com

Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. 

Features Dr. Jack Cush, Editor at RheumNow.com.

Show Notes:

Chinese target emulation trial of MDA-5+, dermatomyositis w/ ILD. 106 Rx w/ UPA & 328 w/ TOFA. 6-month lung transplantation-free survival 72% vs 67% (UPA v TOFA). UPA non-inferior to TOFA in MDA5+DM-ILD https://t.co/BBAfbM06AM

In 2025 DTC TV ad spending by top 10 incr to $2.67 billion (up from $2.1 B). Rheum Drugs in top 3: 1. Skyrizi $440 million 2. Tremfya $431 M 3. Rinvoq $376 M https://t.co/EsWgUqUy9Z

2. Dermatology Salaries 2025 – Dermatology is top 10 at $448K according to Medscape; expected to go down -1% in 2026; derms made up 2% of survey group 37K MDs

3. Itch is common in Scleroderma (SSc) and not related to Dz duration. Study of 2173 Pts (~20K itch assessments), 87 F; mean age 55 yrs; 40% w/ diffuse SSc. Itch (moderate 4/10) seen in ~35% at all times https://t.co/QnT8d0xA5Z

4. Asia-Pacific Lupus study of Mucocutaneous activity (MC-A) in 4102 SLE pts. 36% had MC-A (rash 1055; alopecia 731; m ulcers 352); 15% persistently. MC-A assoc w/ W, smoking, +serologies, vasculitis, myositis, serositis, nephritis, NP-SLE https://buff.ly/D5fXJdY

5. Predictors of Calcinosis Cutis in Systemic Sclerosis  

6. AFFINITY Study - Combination Biologic Therapy in PsA A pilot trial assessed the efficacy and safety of the guselkumab+golimumab (COMBO) combination versus GUS monotherapy in active PsA (failing a prior tumor necrosis factor inhibitor (TNFi-IR) and showed superiority in ACR 50 https://t.co/f2CB8FnZMB

7. AAD 2026 Annual Mtg presents new data on another TYK2 inhibitor. In 2 phase 3 RCTs (ONWARD1 ONWARD2) envudeucitinib was superior to placebo & apremilast in 1700 plaque psoriasis pts https://t.co/DPlzDw5m7N

8. Among 1074 #PsA tested annually, RF positivity was found in 16.1% overall (5.1% RF+ at baseline). RF+ rediced odds of MDA (OR 0.53) w/ incr risk of bDMARD discontinuation (OR 2.65) https://buff.ly/BsM7NKQ

9. The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis - Review

10. Ixekizumab With Tirzepatide Efficacy in Obese Psoriatic Arthritis

11. Brepocitinib in Dermatomyositis

Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week.

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week - including his top four favorite subjects.

Dr. Jack Cush reviews the news and major articles from this week, including FDA safety warnings, reports from AAD, PsA trials.

Dr. Schwartzman and Dr. Ruderman discuss the importance of a domain-based approach in PsA management and consider the potential role of a JAK inhibitor. Sponsored by AbbVie Medical Affairs + Health Impact.  https://buff.ly/9gUnxB7

Dr. Jack Cush reviews the journal reports and news from RheumNow.com.  This week we discuss moral distress, FM in PsA, Lyme Vax is back & hidden but tangible benefits of the MDHAQ.

This month: Multiple FDA regulatory decisions germane to dermatology, psoriasis and lupus; and Eosinophilic Fasciitis (EF) reminder and should you worry about fibromyalgia? Show Notes: 1. FDA Approves Icotrokinra for Plaque Psoriasis The FDA approved an oral IL-23 inhibitor, icotrokinra (Icotyde), for use in moderate-to-severe plaque psoriasis in adults and children 12 years of age and older who are candidates for systemic therapy or phototherapy, according to a https://t.co/q5b3TceFHx 2. FDA has approved secukinumab (Cosentyx) for use pediatric patients (aged 12yrs) with moderate to severe hidradenitis suppurativa  https://t.co/oX4LGU16QP

3. FDA has accepted the supplemental biologics license application for use of interleukin-23 inhibitor tildrakizumab (Ilumya; Sun Pharma) in active psoriatic arthritis (PsA) in adults. https://t.co/cwqz9DoWsL https://t.co/ut0A4MwqW7

4. TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active PsA based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. https://t.co/a6rmortnoS

5.vUCB announced topline results of the BE-BOLD head-to-head study where bimekizumab (IL-17i) was superior to risankizumab (IL-23i) study; 553 active PsA in achieving an ACR50 response at 16 weeks. Enrolled PsA pts were either bilogic naïve or who had previous exposure to 1 TNFi

6. Retrospective TriNetX Network cohort study of adult PsA (N 123,031) pts, propensity- matched to non-PsA controls. PsA had signif higher CV morbidity: MACE (HR 1.74); mortality (HR 1.95); CHF (HR 1.96), MI (HR 1.71), & CVA (HR 1.49). bDMARDs reduced MACE (HR 0.95) & mortality (HR 0.92) vs csDMARDs   https://t.co/bHrq9KpwBM

7. Prevalence of fibromyalgia in PsA = 18%. FM-PsA pts have higher scores Dz activity scores from FM, rather than inflammation. Fibromyalgia is assoc w/ worse disease outcomes, including failure to achieve low disease activity state and poorer response to therapy. https://t.co/utQRXPmpDs

8. JAMA Patient Education Page on JAMA Eosinophilic Fasciitis (EF). EF is rare, but begins with swelling and redness of the arms and/or legs. Later the skin thickens and develops the peau d' orange appearance. EF does not involve fingers or toes, & doesnt have Raynauds https://t.co/WEFFITtmQC

9. REVEAL, a 5-yr real-world study of 236 SLE pts initiating anifrolumab (basekbube SLEDAI-2K 7 for mucocutaneous (67%) & MSK (49%) dz. At 6 months, 26% achieved remission, 66% reached LLDAS, and 57% achieved LLDAS5. Authors claim rapid onset of action https://t.co/16OQatOcPj https://t.co/mU9aciCNcH

10. Update on FDA complete response letter to AZ regarding BLA hold for anifrolumab (Saphnelo) for SC use in SLE. CRL originally issued 10/10/25, but announced 2/3/26. FDA CRL cites critical data quality w/ key analyses in SC-TULIP study. A BLA decision expected in 1st half of 2026 https://t.co/zuwtsdL6I9

11. NEJM: Obinutuzumab in Active Systemic Lupus Erythematosus https://rheumnow.com/news/nejm-obinutuzumab-active-systemic-lupus-erythematosus

Dr. Jack Cush reviews the regulatory actions, news and journal reports from this past week on RheumNow.com

STEP: Obesity and Inflammation: Weight management in Rheumatology. Dr. Uzma Haque  STEP: Mitigating Risk for Rheumatic Disease Patients Undergoing Orthopedic Surgery. Dr. Susan Goodman

STEP: Disease Modification in OA - Dr. Tuhina Neogi STEP: History of Gout  - Dr. Robert Terkeltaub

Rheumatoid Arthritis Faculty Panel Q&A

ILD in RA - Recent Advances. Dr. Jeffrey Sparks

The Mucosal Hypothesis of Rheumatoid Arthritis.  Dr. Kristin Demoruelle

Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau?  Dr. Elena Myasoedova

Dr. Jack Cush reviews the news, regulatory decisions and new journal articles.

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com

Sponsored by AbbVie Medical Affairs + Health Impact 

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.  Features Dr. Jack Cush, Editor at RheumNow.com. 

SHOW NOTES FDA sent a complete response letter to AstraZeneca on their application (BLA) for anifrolumabs (Saphnelo) subcutaneous use in SLE. Despite a positive TULIP-SC trial & EU approval of SC-anifrolumab, FDA & sponsor still have to work things out. CRL reasons are unknown https://t.co/3dNwEyolrj

Review of Calcinosis Cutis - Surgical intervent. most effective (excision, curettage, laser ablation, etc). Medical measures inconsistently, partially effective, best if used early & localized (CCB, TCN, probenecid, immunomodulation, biologics, colchicine, NA thiosulfate, & JAKi https://t.co/rv0hQBv6nX

Systematic Review of Targeted Rx for Systemic Sclerosis: from 32 RCTs & 2036 pts Rx w/ 23 targeted agents. Guselkumab had greatest effect on mRSS, followed by tofacitinib, inebilizumab, & baricitinib. For FVC, B-cell Rx (belimumab, RTX) had highest efficacy https://buff.ly/vHOSRws

Dermatomyositis outcomes w/ 2475 pts (claims) & 1196 pts (EHR). Half had myositis panels & 35% had + MSAbs. Steroid use common in 69% & 74%. HCQ, MTX, MMF. Outocmes (per 1000PYs) wereL all-cause hospitalisation 92, malignancy 15.3, ILD 6.4, and myocarditis 2.1 https://t.co/DJqKGNGX76 Danish DERMBIO registry of psoriasis pts Rx w/ biologics. Among 3790 bionaive pts ustekinumab had best 1-5 yr survival vs (ADA & SEC). In 3403 bioexperienced pts, bimekizumab, guselkumab, & risankizumab had highest 2-year drug survival rate. https://t.co/TInyLPMYkb

Real-world study of 1202 #PsA pts shows that secukinumab retention rates were lower w/ smoking (79%/73%/72% in never/former/current smokers) but not w/ obesity (72%/77%/77% in normal/overweight/obese), Adh HR signif. higher w/ former (1.32) & current smokers (1.27)   https://t.co/1REWmod73W

Together PSO Trial - Combination Ixekizumab and Tirzepatide Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over https://t.co/YWCjN2NyGM

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Highlights include referral rules, combination biiologics in psoriasis and don't use JAK inhibitors in pregnancy.

Dr.Jack Cush reviews the hot item takeaways from last weeks RheumNow.Live 2026 Diet & Obesity Management in Rheumatology - Uzma Haque, MD Mitigating risk for Rheum patients undergoing orthopedic surgery - Susan Goodman, MD Paradoxical skin reactions – Dr. Joseph Merola Mortality in RA  - Elena Myasoedova, MD The Mucosal Hypothesis to RA - Kristin Demourelle, MD Advances in ILD - Jeffrey Sparks, MD Seronegative vs. Seropositive RA - Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com